Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease characterized by irreversible scarring of the lung tissue. Current therapeutic options are limited and often accompanied by significant systemic side effects. In search of safer and more targeted treatment strategies, an international team of researchers led by Prof. Andreas Günther (Justus-Liebig-University Giessen) evaluated LTI-03, a novel caveolin-1 peptide mimetic delivered directly into the lungs via inhalation.

In a randomized, double-blind, placebo-controlled Phase 1b clinical trial, the safety, tolerability, and biological activity of inhaled LTI-03 were assessed in patients with IPF over a 14-day treatment period. Inhalation of LTI-03 was well tolerated with a favorable safety profile, showing no negative impact on patient quality of life or aggravation of chronic cough symptoms compared to placebo.

Importantly, exploratory biomarker analyses, which were based on preclinical studies employing human IPF-derived precision cut lung slices (iScience. 2025 Aug 26;28(9):113437. doi: 10.1016/j.isci.2025.113437), demonstrated a significant dose-dependent reduction in key pro-fibrotic and inflammatory proteins driving IPF pathogenesis, including, amongst others, Interleukin-11 (IL-11) and SP-D. By targeting damaged alveolar epithelial cells and fibroblasts directly at the site of disease, inhaled LTI-03 represents a promising local therapeutic approach to arrest fibrotic remodeling in IPF. Further clinical development will evaluate its efficacy in long-term treatment settings.

Find the full article here: https://doi.org/10.1038/s41467-026-75291-3